{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:40:55Z","timestamp":1792201255362,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:00:00Z","timestamp":1570406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:00:00Z","timestamp":1570406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-019-1530-9","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T18:03:38Z","timestamp":1570471418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Influenza A(H5N1) Virus Subunit Vaccine Administered with CaPNP Adjuvant Induce High Virus Neutralization Antibody Titers in Mice"],"prefix":"10.1208","volume":"20","author":[{"given":"Tulin","family":"Morcol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peri","family":"Nagappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J. D.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Cawthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,7]]},"reference":[{"key":"1530_CR1","unstructured":"WHO consultation and information meeting on the composition of influenza virus vaccines for the northern hemisphere 2016\u20132017. Available at: www.who.int\/influenza\/vaccines\/virus\/recommendations\/consultation201602\/en\/index2.html"},{"key":"1530_CR2","unstructured":"NIAID Strategic Plan for Research on Vaccine Adjuvants. Available at: https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/NIAID-StrategicPlanVaccineAdjuvants.pdf"},{"key":"1530_CR3","unstructured":"WHO, Cumulative number of confirmed human cases for H5N1, 2003\u20132017 http:\/\/www.who.int\/influenza\/human_animal_interface\/2017_06_15_tableH5N1-corrected.pdf?ua=1"},{"key":"1530_CR4","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1001\/jama.297.18.2025","volume":"297","author":"JK Taubenberger","year":"2007","unstructured":"Taubenberger JK, Morens DM, Fauci AS. The next influenza pandemic: can it be predicted? JAMA. 2007;297:2025\u20137.","journal-title":"JAMA"},{"key":"1530_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMoa044021","volume":"352","author":"K Ungchusak","year":"2005","unstructured":"Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza a (H5N1). N Engl J Med. 2005;352:333\u201340.","journal-title":"N Engl J Med"},{"key":"1530_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1586\/14760584.2016.1115352","volume":"15","author":"F He","year":"2016","unstructured":"He F, Leyrer S, Kwang J. Strategies towards universal pandemic influenza vaccines. Expert Rev Vaccines. 2016;15:215\u201325.","journal-title":"Expert Rev Vaccines"},{"key":"1530_CR7","doi-asserted-by":"crossref","unstructured":"Editorial-The Lancet. Plotting a route to a universal influenza vaccine. Lancet Infect Dis 2018;18: 475.","DOI":"10.1016\/S1473-3099(18)30235-4"},{"key":"1530_CR8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1586\/14760584.2015.1068125","volume":"14","author":"AK Wheatley","year":"2015","unstructured":"Wheatley AK, Kent SJ. Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity. Expert Rev Vaccines. 2015;14:1227\u201339.","journal-title":"Expert Rev Vaccines"},{"key":"1530_CR9","first-page":"Article 285","volume":"5","author":"S Quinones-Parra","year":"2014","unstructured":"Quinones-Parra S, Loh L, Brown LE, Kedzierska K, Valkenburg SA. Universal immunity to influenza must outwit immune evasion. Front Microbiol. 2014;5:Article 285.","journal-title":"Front Microbiol"},{"key":"1530_CR10","unstructured":"WHO, \u201cGlobal pandemic influenza action plan to increase vaccine supply,\u201d Tech. Rep. WHO\/IVB\/06.13; WHO\/CDS\/EPR\/GIP\/2006.1, WHO, Geneva, 2006, http:\/\/whqlibdoc.who.int\/hq\/2006\/WHO_IVB_06.13_eng.pdf?ua=1"},{"key":"1530_CR11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMoa055778","volume":"354","author":"JJ Treanor","year":"2006","unstructured":"Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza a (H5N1) vaccine. N Engl J Med. 2006;354:1343\u201351.","journal-title":"N Engl J Med"},{"key":"1530_CR12","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/S0264-410X(00)00395-9","volume":"19","author":"JJ Treanor","year":"2001","unstructured":"Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine. 2001;19:1732\u20137.","journal-title":"Vaccine."},{"key":"1530_CR13","unstructured":"HHS, Office of ASPR, Medical Countermeasures (MCM). Pandemic Influenza: Current vaccine and adjuvant stockpiles. Available at: https:\/\/www.medicalcountermeasures.gov\/media\/35695\/cioce_current_vaccine_and_adjuvant_stockpiles.pdf"},{"key":"1530_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev.med.57.121304.131333","volume":"57","author":"DB Lewis","year":"2006","unstructured":"Lewis DB. Avian fl u to human infl uenza. Annu Rev Med. 2006;57:139\u201354.","journal-title":"Annu Rev Med"},{"key":"1530_CR15","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3201\/eid1310.061262","volume":"13","author":"A Haque","year":"2007","unstructured":"Haque A, Hober D, Kasper LH. Confronting potential influenza a (H5N1) pandemic with better vaccines. Emerg Infect Dis. 2007;13:1512\u20138.","journal-title":"Emerg Infect Dis"},{"key":"1530_CR16","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","volume":"365","author":"T Vesikari","year":"2011","unstructured":"Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011;365:1406\u201316.","journal-title":"N Engl J Med"},{"key":"1530_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S2213-2600(18)30108-5","volume":"6","author":"T Vesikari","year":"2018","unstructured":"Vesikari T, Kirstein J, Devota Go G, Leav B, Ruzycky ME, Isakov L, et al. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. Lancet Respir Med. 2018;6:345\u201356.","journal-title":"Lancet Respir Med"},{"key":"1530_CR18","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1128\/JVI.01939-10","volume":"85","author":"JMA van den Brand","year":"2011","unstructured":"van den Brand JMA, Kreijtz JHCM, Bodewes R, Stittelaar KJ, van Amerongen G, Kuiken T, et al. Efficacy of vaccination with different combinations of MF59-Adjuvanted and Nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J Virology. 2011;85:2851\u20138.","journal-title":"J Virology"},{"key":"1530_CR19","unstructured":"European Centre for Disease Prevention and Control. Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation) Stockholm: ECDC; September 2012, Stockholm, Sweden, ISBN 978\u201392\u20139193-388-4. (VAESCO report)."},{"key":"1530_CR20","unstructured":"Reilly J. Final Report of National Narcolepsy Study Steering Committee, Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010. April 476 19, 2012. Available at: https:\/\/health.gov.ie\/wp-content\/uploads\/2014\/03\/Final_Report_of_National_Narcolepsy_Study_Steering_Committee.pdf. Accessed February 9, 2015 and Jan 6, 2019."},{"key":"1530_CR21","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1093\/brain\/awt187","volume":"136","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Arnulf I, Lecendreux M, Monaca Charley C, Franco P, Drouot X. Et a. Narcoflu-VF study group. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain. 2013;136:2486\u201396.","journal-title":"Brain"},{"key":"1530_CR22","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s11095-009-9859-5","volume":"26","author":"BC Baudner","year":"2009","unstructured":"Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, Singh M, et al. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res. 2009;26:1477\u201385.","journal-title":"Pharm Res"},{"key":"1530_CR23","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1080\/21645515.2015.1046660","volume":"11","author":"V Iyer","year":"2015","unstructured":"Iyer V, Cayatte C, Guzman B, Schneider-Ohrum K, Matuszak R, Snell A, et al. Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants. Hum Vaccin Immunother. 2015;11:1853\u201364.","journal-title":"Hum Vaccin Immunother"},{"key":"1530_CR24","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/vaccines3040930","volume":"3","author":"D Boraschi","year":"2015","unstructured":"Boraschi D, Italiani P. From antigen delivery system to Adjuvanticy: the board application of nanoparticles in vaccinology. Vaccines (Basel). 2015;3:930\u20139.","journal-title":"Vaccines (Basel)"},{"key":"1530_CR25","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1016\/j.vaccine.2017.07.016","volume":"35","author":"T Mor\u00e7\u04e7l","year":"2017","unstructured":"Mor\u00e7\u04e7l T, Hurst BL, Tarbet EB. Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza a (H1N1) 2009 vaccine in mice. Vaccine. 2017;35:4569\u201377.","journal-title":"Vaccine."},{"key":"1530_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.vetmic.2009.05.004","volume":"139","author":"DH Joyappa","year":"2009","unstructured":"Joyappa DH, Kumar CA, Banumathi N, Reddy GR, Suryanarayana VVS. Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1-3CD gene construct protects mice and Guinea pigs against the challenge virus. Vet Microbiol. 2009;139:58\u201366.","journal-title":"Vet Microbiol"},{"key":"1530_CR27","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/CDLI.7.6.899-903.2000","volume":"6","author":"Q He","year":"2000","unstructured":"He Q, Mitchell A, Johnson SL, Wagner-Bartak C, Morcol T, Bell SJD. Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol. 2000;6:899\u2013903.","journal-title":"Clin Diagn Lab Immunol"},{"key":"1530_CR28","first-page":"1021","volume":"9","author":"Q He","year":"2002","unstructured":"He Q, Mitchell AR, Johnson SL, Morcol T, Bell SJD. Calcium phosphate particles induced mucosal immunity and protection against herpes simplex V2. Clin Diagnos Lab Immunol. 2002;9:1021\u20134.","journal-title":"Clin Diagnos Lab Immunol"},{"key":"1530_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3109\/1547691X.2013.772267","volume":"11","author":"H Olmedo","year":"2013","unstructured":"Olmedo H, Herrera M, Rojas L, et al. Comparison of the adjuvant activity of aluminum hydroxide and calcium phosphate on the antibody response towards Bothrops asper snake venom. J Immunotoxicol. 2013;11:44\u20139.","journal-title":"J Immunotoxicol"},{"key":"1530_CR30","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.rvsc.2010.09.008","volume":"91","author":"S Koppad","year":"2011","unstructured":"Koppad S, Raj GD, Gopinath VP, Kirubaharan JJ, Thangavelu A, Thiagarajan V. Calcium phosphate coupled Newcastle disease vaccine elicits humoral and cell mediated immune responses in chickens. Res Vet Sci. 2011;91:384\u201390.","journal-title":"Res Vet Sci"},{"key":"1530_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s12257-016-0326-y","volume":"21","author":"Y Amini","year":"2016","unstructured":"Amini Y, Moradi B, Tafaghodi M, Meshkat Z, Ghazvini K, Fasihi-Ramandi MTB. Trifusion antigen adsorbed on calcium phosphate nanoparticles stimulates strong cellular immunity in mice. Biotechnol Bioprocess Eng. 2016;21:653\u20138.","journal-title":"Biotechnol Bioprocess Eng"},{"key":"1530_CR32","first-page":"5","volume":"XXXX","author":"HM Karam","year":"2015","unstructured":"Karam HM, Shaaban EA, Mohamed AF, Zaki HF, Kenawy SA. New approach for improving production of Naja Haje snake antivenom. Int J Science Res Publications. 2015;XXXX:5.","journal-title":"Int J Science Res Publications"},{"key":"1530_CR33","unstructured":"CaPtivate Pharmaceuticals Reports Data from Influenza A\/H1N1 2009 Pandemic virus vaccine studies funded by NIAID\/NIH preclinical services program: CaP nanoparticle adjuvant significantly improves vaccine efficacy. Available at: http:\/\/www.ireachcontent.com\/news-releases\/captivate-pharmaceuticals-reports-data-from-influenza-ah1n1-2009-pandemic-virus-vaccine-studies-funded-by-niaidnih-preclinical-services-program-671631134.html"},{"key":"1530_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1208\/s12249-017-0847-5","volume":"19","author":"T Mor\u04abol","year":"2018","unstructured":"Mor\u04abol T, Weidner JM, Mehta A, Bell SJD, Block T. Calcium phosphate particles as pulmonary delivery system for interferon-\u03b1 in mice. AAPS PharmSciTech. 2018;19:395\u2013412.","journal-title":"AAPS PharmSciTech"},{"key":"1530_CR35","unstructured":"Mor\u00e7ol T, Nagappan P, Nerenbaum L, Mitchell A, Bell, SJD. (2006) Particulate Drug Delivery Systems for Protein Drugs: An Overview of Non-invasive Insulin Delivery Using Calcium Phosphate Particle Technology in: Handbook of Particulate Drug Delivery, Chapter 11, Kumar, R.M.N.V. (Ed.), American Scientific Publishers, Stevenson Ranch, CA."},{"key":"1530_CR36","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","volume":"18","author":"J Banchereau","year":"2000","unstructured":"Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767\u2013811.","journal-title":"Annu Rev Immunol"},{"key":"1530_CR37","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1080\/21645515.2017.1369639","volume":"13","author":"X Huang","year":"2017","unstructured":"Huang X, Karabudak A, Comber J, Morcol T, Philip R. Novel vaccination approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles. Human Vaccines Immothera. 2017;13:2612\u201325. https:\/\/doi.org\/10.1080\/21645515.2017.1369639.","journal-title":"Human Vaccines Immothera"},{"key":"1530_CR38","volume-title":"327\u2013358","author":"DT O\u2019Hagan","year":"2011","unstructured":"O\u2019Hagan DT, Tsai T, Reed S. Emulsion based adjuvants for improved influenza vaccine in: influenza vaccines for the future. Del Giudice G, Rappuoli R (Eds). Springer; Basel AG. In: 327\u2013358; 2011."},{"key":"1530_CR39","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","volume":"30","author":"DT O\u2019Hagan","year":"2012","unstructured":"O\u2019Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine. 2012;30:4341\u20138.","journal-title":"Vaccine"},{"key":"1530_CR40","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.vaccine.2009.10.017","volume":"28","author":"I Leroux-Roels","year":"2010","unstructured":"Leroux-Roels I, Roman F, Forgus S, Maes C, de Boever F, Dram\u00e9 M, et al. Priming with AS03-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomized extension of a double-blind randomized primary study. Vaccine. 2010;28:849\u201357.","journal-title":"Vaccine"},{"key":"1530_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/erv.12.140","volume":"12","author":"DT O\u2019Hagan","year":"2013","unstructured":"O\u2019Hagan DT, Ott GS, Nest GV, Rappuoli R. DelGiudice. The history of MF59\u00ae adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013;12:13\u201330.","journal-title":"Expert Rev Vaccines"},{"key":"1530_CR42","unstructured":"Seasonal Flu Vaccine Fluad Approved by FDA. Deceber 02, 2015. Available at: https:\/\/www.pharmacytimes.com\/product-news\/seasonal-flu-vaccine-fluad-approved-by-fda."},{"key":"1530_CR43","unstructured":"BioSante Pharmaceuticals, Inc. Announces CaP Nanotechnology Product Development-New Product. February 5, 2004. Available at: https:\/\/www.azonano.com\/article.aspx?ArticleID=477"},{"key":"1530_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","volume":"5","author":"MA Ramakrishnan","year":"2016","unstructured":"Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol. 2016;5:85\u20136.","journal-title":"World J Virol"},{"key":"1530_CR45","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1128\/JVI.73.7.5903-5911.1999","volume":"73","author":"X Lu","year":"1999","unstructured":"Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM. A mouse model for the evaluation of pathogenesis and immunity to influenza a (H5N1) viruses isolated from humans. J Virology. 1999;73:5903\u201311.","journal-title":"J Virology"},{"key":"1530_CR46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41541-017-0017-5","volume":"16","author":"S-S Wong","year":"2017","unstructured":"Wong S-S, DeBeauchamp J, Zanin M, Sun Y, Tang J, Webby R. H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines. NPJ Vaccines. 2017;16:16. https:\/\/doi.org\/10.1038\/s41541-017-0017-5.","journal-title":"NPJ Vaccines"},{"key":"1530_CR47","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00705-019-04147-7","volume":"164","author":"A Nurpeisova","year":"2019","unstructured":"Nurpeisova A, Kassenov M, Rametov N, Tabynov K, Renukaradhya GJ, Volgin Y, et al. Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine. Arch Virol. 2019;164:1027\u201336.","journal-title":"Arch Virol"},{"key":"1530_CR48","doi-asserted-by":"publisher","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","volume":"7","author":"H Nohynek","year":"2012","unstructured":"Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One. 2012;7:e33536.","journal-title":"PLoS One"},{"key":"1530_CR49","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1016\/j.vaccine.2013.10.033","volume":"31","author":"I Rouleau","year":"2013","unstructured":"Rouleau I, De Serres G, Drolet JP, Skowronski DM, Ouakki M, Toth E. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic a\/H1N1 (H1N1pdm09) vaccine. Vaccine. 2013;31:5989\u201396.","journal-title":"Vaccine."},{"key":"1530_CR50","first-page":"324","volume":"58","author":"DJ Padilla-Carlin","year":"2008","unstructured":"Padilla-Carlin DJ, McMurray DN, Hickey AJ. The Guinea pig as a model of infectious diseases. Comp Med. 2008;58:324\u201340.","journal-title":"Comp Med"},{"key":"1530_CR51","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0264-410X(02)00548-0","volume":"21","author":"PJ Hogarth","year":"2013","unstructured":"Hogarth PJ, Jahans KJ, Hecker R, Hewinson RG, Chambers MA. Evaluation of adjuvants for protein vaccines against tuberculosis in Guinea pigs. Vaccine. 2013;21:977\u201382.","journal-title":"Vaccine"},{"key":"1530_CR52","first-page":"131","volume":"65","author":"EH Relyveld","year":"1986","unstructured":"Relyveld EH. Preparation and use of calcium phosphate adsorbed vaccines. Dev Biol Stand. 1986;65:131\u20136.","journal-title":"Dev Biol Stand"},{"key":"1530_CR53","volume-title":"3971","author":"Ph.Eur. 6.ed","year":"2009","unstructured":"Ph.Eur. 6.ed. Vaccines for human use, pp. In: 3971; 2009."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1530-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-019-1530-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1530-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T01:55:16Z","timestamp":1744077316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-019-1530-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,7]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["1530"],"URL":"https:\/\/doi.org\/10.1208\/s12249-019-1530-9","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,7]]},"assertion":[{"value":"10 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All immunization studies were performed at BioCon Inc. (Rockville, MD) in the company\u2019s Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC)-accredited Laboratory Animal Research Facility. Animals were housed according to Office of Laboratory Animal Welfare (OLAW) and AAALAC Guidelines. All animal experiments and related protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of BioCon. Experiments were conducted in accordance with the guidelines set out by the AAALAC. Acute toxicity studies were performed separately with contract to IIT Research Institute (IITRI-Chicago, IL.) and\u00a0in accordance with U.S. Food and Drug Administration (FDA) Good Laboratory Practice (GLP) Regulations as set forth in the Code of Federal Regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"315"}}